Boston Scientific Corporation $BSX Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC grew its position in Boston Scientific Corporation (NYSE:BSX) by 507.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,862 shares of the medical equipment provider’s stock after buying an additional 63,382 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Boston Scientific were worth $7,406,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares in the last quarter. State Street Corp boosted its stake in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC boosted its stake in shares of Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. grew its holdings in shares of Boston Scientific by 1.4% in the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after purchasing an additional 226,578 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BSX. Evercore reduced their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Truist Financial cut their price objective on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Citigroup reduced their price objective on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Finally, Morgan Stanley lowered their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Stock Down 2.4%

Shares of NYSE:BSX opened at $71.24 on Friday. The firm has a 50 day simple moving average of $85.03 and a 200-day simple moving average of $94.55. Boston Scientific Corporation has a twelve month low of $70.75 and a twelve month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $105.71 billion, a PE ratio of 36.72, a P/E/G ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the firm posted $0.70 EPS. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.50% of the stock is owned by corporate insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.